May 7, 2013 — UltraSPECT has announced its distribution agreement with PharmaLogic for the sale of UltraSPECT’s cardiac and bone imaging applications. The agreement will enable PharmaLogic to provide its hospitals and imaging centers with access to UltraSPECT’s Xpress line of products for lower radiation dose with no diminished image quality.
“UltraSPECT’s proprietary Wide-Beam Reconstruction technology enables our customers to achieve significant radiation dose reduction combined with greater patient comfort and higher throughput capacity,” said Steve Chilinski, president and CEO of PharmaLogic. “Even better, this technology can be easily implemented by retrofitting our customers’ existing facilities without the cost of new imaging camera systems."
Through the use of UltraSPECT’s innovative Wide-Beam Reconstruction (WBR) technology, the products in the company’s portfolio of solutions can provide two unique advantages. They significantly reduce the standard radiopharmaceutical dose requirements for cardiac and bone nuclear medicine imaging exams and/or cut the imaging procedure time in half while maintaining the image quality the facility is accustomed to. Many times they even enhance the image resolution. The company’s Xpress3.Cardiac solution provides benefits — enabling nuclear exams to be performed with 50 percent reduction in both dose and procedure time.
Both patients and technologists benefit from these improvements. With shorter exam times, patient comfort is increased with reduced risk of artifacts from patient movement. Higher image resolution provides greater lesion localization, raising diagnostic confidence and precision. For many UltraSPECT users, the WBR technology results in higher patient throughput for enhanced equipment utilization, higher revenues and greater patient satisfaction and referrals.
UltraSPECT’s product line, utilizing WBR technology, is compatible with most major manufacturers’ nuclear medicine systems as well as clinical software packages.
For more information: www.ultraspect.com
July 30, 2024 
